Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report.

about

Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report.

Item

http://www.wikidata.org/entity/Q42259474

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pathological complete response ...... th bevacizumab: A case report.

@en

Pathological complete response ...... erapy with S-1 and oxaliplatin

@nl

type

Item

label

Pathological complete response ...... th bevacizumab: A case report.

@en

Pathological complete response ...... erapy with S-1 and oxaliplatin

@nl

prefLabel

Pathological complete response ...... th bevacizumab: A case report.

@en

Pathological complete response ...... erapy with S-1 and oxaliplatin

@nl

P1476

Pathological complete response ...... th bevacizumab: A case report.

@en

P2093

Daisuke Takahari

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kohei Shitara

http://www.w3.org/2001/XMLSchema#string

Masahiro Shimura

http://www.w3.org/2001/XMLSchema#string

Takashi Ura

http://www.w3.org/2001/XMLSchema#string

Tomoya Yokota

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Sano

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Shimizu

http://www.w3.org/2001/XMLSchema#string

Yoshiki Senda

http://www.w3.org/2001/XMLSchema#string

Yuji Nimura

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Trends in long-term survival following liver resection for hepatic colorectal metastases.

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.

Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.

Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.

Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.

P304

201-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2011.256

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yasushi Yatabe

P577

2011-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230621042

http://www.w3.org/2001/XMLSchema#string

P698

22866064

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

3410587

http://www.w3.org/2001/XMLSchema#string